Welcome to our dedicated page for Jade Biosciences SEC filings (Ticker: JBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Jade Biosciences, Inc. files a prospectus supplement to the S-1 registering common stock for resale by a selling stockholder.
The supplement incorporates by reference the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The filing discloses 49,316,287 shares outstanding as of February 28, 2026 and a last reported Nasdaq sale price of $13.88 per share on March 5, 2026.
Jade Biosciences, Inc. describes its business as a clinical-stage biopharmaceutical company focused on novel biologic therapies for autoimmune diseases. The lead antibody, JADE101, targets APRIL for IgA nephropathy, with a Phase 1 trial in healthy volunteers started in August 2025 and a Phase 2 IgAN trial planned for mid-2026.
JADE201, an afucosylated, half-life extended anti-BAFF-R antibody, is being advanced toward a Phase 1 trial in rheumatoid arthritis patients in the second quarter of 2026. A third program, JADE301, targets an undisclosed pathway with a first-in-human trial expected in 2027.
The company outlines a large IgA nephropathy opportunity, citing an FDA-estimated U.S. prevalence of 169,000 patients and a U.S. addressable market of approximately $20 billion, and highlights collaborations and license agreements with Paragon and major biologics manufacturers to support development and manufacturing.
Jade Biosciences reported fourth quarter and full year 2025 results and detailed progress across its autoimmune disease pipeline. The company ended December 31, 2025 with cash, cash equivalents and investments of $336,158 thousand and total assets of $349,781 thousand.
Total liabilities were $17,263 thousand and stockholders’ equity was $332,518 thousand, compared with a deficit a year earlier. For 2025, research and development expenses were $93,121 thousand and general and administrative expenses were $20,421 thousand, leading to a net loss of $127,410 thousand.
The net loss per share attributable to common stockholders was $3.19 basic and diluted. Management highlighted clinical momentum for JADE101 in Phase 1 for IgA nephropathy, plans to start a Phase 2 trial and first-in-human dosing of JADE201, and an expected cash runway extending into the first half of 2028.
Sofinnova-linked funds and principals now report a much smaller stake in Jade Biosciences, Inc. common stock. The group, including Sofinnova Venture Partners X and related entities, beneficially owns 107,391 shares, representing about 0.3% of the company’s common stock based on 32,626,730 shares outstanding as of September 30, 2025.
The update follows the April 28, 2025 merger between Jade Biosciences, Inc. and Aerovate Therapeutics, Inc., preceded by a 1-for-35 reverse stock split. As a result of these corporate actions, the Sofinnova group ceased to own more than 5% of Jade Biosciences’ outstanding common shares but continues to hold its position for investment purposes.
Jade Biosciences, Inc. (JBIO) received an amended Schedule 13G reporting that Venrock Healthcare funds and related entities collectively beneficially own 5,115,862 shares of common stock and pre-funded warrants, representing 9.99% of the company’s common stock as of December 31, 2025.
The holdings are spread across several Venrock vehicles, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P., with management entities and individuals Nimish Shah and Bong Koh having shared voting and dispositive power.
The pre-funded warrants include a “Beneficial Ownership Blocker” that prevents exercise if ownership would exceed 9.99% of Jade Biosciences’ outstanding common stock. The filers certify that the securities are not held for the purpose of changing or influencing control of the company.
Bellevue Group AG, through its wholly owned subsidiary Bellevue Asset Management AG, reported a significant passive ownership stake in Jade Biosciences, Inc. common stock. They beneficially own 3,341,103 shares, representing 6.8% of the outstanding common stock, with shared voting and dispositive power over all of these shares.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Jade Biosciences. Bellevue and its subsidiary certify that the information provided is true, complete, and correct.
Janus Henderson Group plc filed a Schedule 13G reporting a passive ownership stake in Jade Biosciences, Inc. common stock. Through its investment adviser subsidiaries managing various client accounts, it is deemed the beneficial owner of 3,063,457 shares, representing 6.2% of the class.
These shares are held with shared voting and dispositive power, while Janus Henderson’s asset managers exercise investment and voting discretion for client portfolios. The managed portfolios retain rights to dividends and sale proceeds. Janus Henderson certifies the holdings are in the ordinary course of business and not intended to change or influence control of Jade Biosciences.
Jade Biosciences Chief Financial Officer Bradford D. Dahms received new equity awards on February 12, 2026. He was granted 37,813 shares of common stock in the form of restricted stock units at no cash cost, each representing a right to one share.
These RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2026, contingent on continued service. Dahms was also granted stock options for 226,875 shares of common stock with a $14.81 exercise price, granted at no cost.
One quarter of the options vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, also subject to his continued service. All reported holdings are shown as directly owned.
Jade Biosciences, Inc. granted equity awards to Chief Legal Officer and Corporate Secretary Elizabeth Balta. On February 12, 2026, she received 28,125 shares of common stock in the form of restricted stock units at $0 per share and a stock option for 168,750 shares with a $14.81 exercise price.
The RSUs vest in four equal parts on each of the first four anniversaries of February 15, 2026, if she remains in service. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, also contingent on continued service.
Frohlich Tom reported acquisition or exercise transactions in a Form 4 filing for JBIO. The filing lists transactions totaling 551,250 shares. Following the reported transactions, holdings were 472,500 shares.